This Pradaxa MDL Case Will Include Gastrointestinal Bleeding And Other Hemorrhages As Well As Heart Attacks Or Myocardial Infarctions
Pradaxa is a blood-thinning drug used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem. Since coming on the market in October 2010 the FDA has received numerous Adverse Event Reports involving:
• Serious bleeding side effects
• Hemorrhages such as hemorrhagic stroke
In addition, some medical studies have associated Pradaxa with an increased risk:
• Heart attack
• Myocardial infarction (MI)
• Acute coronary syndrome (ACS)
Due to these serious side effects, a growing number of personal injury and wrongful death Pradaxa lawsuits have been filed against these defendants: Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Vetmedica, Inc.; Boehringer Ingelheim Roxane, Inc.; Boehringer Ingelheim Corp.; and, Boehringer Ingelheim USA Corp.
Strictly Confidential, No Obligation.
On August 8, 2012 the United States Judicial Panel on Multidistrict Litigation (JPML) issued an Order (PDF) which consolidated all federal court Pradaxa drug injury lawsuits into the following case: IN RE: PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION, MDL No. 2385.
The details of this federal court Pradaxa Mulitdistrict Litigation (MDL) can be found in these selected parts from that August 2012 JPML Order:
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization under Section 1407 in the Southern District of Illinois will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All the actions share common factual questions arising out of allegations that plaintiffs suffered severe bleeding or other injuries as a result of taking the drug Pradaxa (dabigatran etexilate) and that defendants did not adequately warn prescribing physicians of the risks associated with Pradaxa, including the potential for severe or fatal bleeding, and that there is no reversal agent to counteract the Pradaxa’s anticoagulation effects....
... Thirteen of the forty related actions (including potential tag-along actions) are pending in that district.... Further, centralization in this district will facilitate coordination with pending state court litigation, including an action pending in Southern Illinois encompassing claims of over seventy plaintiffs. Finally, by selecting Judge David R. Herndon to preside over this matter, we are selecting a jurist with the willingness and ability to handle this litigation....
We will continue to monitor developments in this federal court Pradaxa MDL and report significant developments, here.
You can learn more about these personal injury and wrongful death Pradaxa lawsuits at the Pradaxa Information page on our Drug Injury Law web site.
DrugInjuryLaw.com: Legal Information And News About Prescription Drug Side Effects
Drug Injury Case Evaluation - Free & Confidential